Skip to main content
Todd Fehniger, MD, Oncology, Saint Louis, MO, Barnes-Jewish Hospital

ToddAFehnigerMDPhD

Oncology • Saint Louis, MO

Hematologic Oncology

Associate Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Fehniger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Fehniger's full profile

Already have an account?

Summary

  • Dr. Todd Fehniger is an oncologist in Saint Louis, MO and is affiliated with multiple hospitals in the area, including Barnes-Jewish Hospital and Siteman Cancer Center. He received his medical degree from The Ohio State University College of Medicine and has been in practice 15 years. He specializes and is board certified in medical oncology and is experienced in blood cancers (leukemia, lymphoma, and related diseases), hematopoietic cell transplantation (bone marrow transplantation, cellular therapy (CAR T cells).

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2004 - 2008
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2002 - 2004
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 2002

Certifications & Licensure

  • MO State Medical License
    MO State Medical License 2004 - 2025
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Deep Learning Approach to Automate Refinement of Somatic Variant Calling from Cancer Sequencing Data  
    Ravindra Uppaluri, Gavin P Dunn, Ramaswamy Govindan, S Joshua Swamidass, Todd A Fehniger, Nature
  • Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation  
    M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

  • Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors
    Todd A Fehniger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after...
    Todd A Fehniger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses
    Todd A Fehniger, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • The Making of Memory 
    60th American Society of Hematology Annual Meeting - 12/1/2018
  • Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • For Children, Young Adults with Recurrent AML, Immunotherapy Shows Promise
    For Children, Young Adults with Recurrent AML, Immunotherapy Shows PromiseDecember 10th, 2021
  • Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-in-Class AML Program, and Initiate Multiple Solid Tumor Trials
    Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-in-Class AML Program, and Initiate Multiple Solid Tumor TrialsJuly 15th, 2021
  • Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer Cells
    Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer CellsMay 13th, 2021
  • Join now to see all

Grant Support

  • Molecular Mechanisms Of Natural Killer Cell Cytokine-ActivationNational Heart, Lung, And Blood Institute2009–2012

Hospital Affiliations

External Links

Dr. Todd Fehniger, Dr. Todd Fehniger, MD, Dr. T Fehniger, Dr. Todd A Fehniger